Atlas Venture Life Science Advisors
$631M 13F equity value
9 Holdings
Quarter ended September 30, 2026
The latest 13F on file for Atlas Venture Life Science Advisors covers the quarter ended September 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc. | 2,847,541 | $318M | 50.4% |
| IRON | Disc Medicine, Inc. | 1,384,025 | $91M | 14.4% |
| OBX | Obsidian Therapeutics, Inc. | 4,503,149 | $62M | 9.8% |
| KLRA | Kailera Therapeutics, Inc. | 5,171,282 | $59M | 9.4% |
| DYN | Dyne Therapeutics, Inc. | 3,440,720 | $55M | 8.8% |
| QTTB | Q32 Bio, Inc. | 2,717,106 | $22M | 3.6% |
| SION | Sionna Therapeutics, Inc. | 2,995,602 | $16M | 2.5% |
| KRRO | Korro Bio, Inc. | 773,260 | $8M | 1.2% |
| ODTX | Odyssey Therapeutics, Inc. | 2,692 | $59,816 |
Track Atlas Venture Life Science Advisors's 13F portfolio: $631M in reported holdings, 9 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}